FULC Stock — Fulcrum Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.76

Market cap

$286.9M

Cash

$318.8M

Enterprise value

-$31.9M

Balance sheet

Cash	$318.8M
Debt	$0.0M
Net cash	$318.8M
Enterprise value	-$31.9M
Basic shares	76.3M shares
Fully diluted shares	94.1M shares
Fully diluted market cap	$353.8M
Cash per share	$4.18

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading FULC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 18 - Apr 29	Pociredir	Phase 2	Sickle Cell Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

pociredir

Phase 1 · Terminated Modality: small molecule (oral)

Target PRC2

Partnerships n/a (all rights retained)

Indications

Sickle cell disease (SCD) (Phase 1)

Status note Discontinued June 2026 following end-of-Phase-I meeting minutes (received late May 2026) reflecting heightened FDA concerns on benefit-risk in SCD, informed by preclinical hematologic malignancy observations with pociredir and malignancy signals reported with other PRC2 inhibitors. Company subsequently ceased R&D activities, initiated a restructuring (~85% workforce reduction) and is evaluating strategic alternatives.

losmapimod

Phase 3 · Terminated Modality: small molecule (oral)

Partnerships Genzyme/Sanofi (ex-U.S. commercialization license, May 2024; Sanofi terminated for convenience December 2024; agreement ended April 17, 2025)

Indications

Facioscapulohumeral muscular dystrophy (FSHD) (Phase 3)

Status note Development discontinued September 2024 following Phase 3 REACH topline results.

CAMP4-licensed DBA program

Preclinical · Terminated Modality: small molecule

Partnerships CAMP4 Therapeutics (worldwide exclusive license, July 2023; notice to terminate delivered April 23, 2026)

Indications

Bone marrow failure syndromes, including Diamond-Blackfan anemia (DBA) (Preclinical)

Status note Bone marrow failure syndromes program, including DBA, discontinued February 2026.

FTX-6274

Preclinical · Active Modality: small molecule (oral)

Target EED

Indications

Prostate cancer (Preclinical)

Status note Oral EED inhibitor candidate; preclinical data presented at ESMO 2025. Company ceased R&D activities in June 2026 and is evaluating strategic alternatives; no product candidates in active clinical development.

Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Pociredir
Lead indication	Sickle Cell Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07401823	Phase 2	Enrolling by invitation	Sponsor	Fulcrum Therapeutics	—	Sickle Cell Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Fulcrum Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,565,029	+1,434,469	0.27%	2026-08-14
Ikarian Capital	1,049,161	no change	0.63%	2026-08-14
Braidwell LP	0	-3,134,922	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

FULC — Fulcrum Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders